G9019 HCPCS Level II Code: Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)
Medicare Coverage & Payment
- CMS short descriptor: Oseltamivir phosphate 75mg
- Medicare coverage: Carrier judgment (CMS coverage code C)
- Pricing indicator: 13
- BETOS: O1E — Other drugs
- Last CMS action effective: January 1, 2020
- Terminated: December 31, 2019
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Code Set: Removed from the code set — not valid on or after January 1, 2020.
Contextual Map
Every relationship of G9019 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Nearest codes (40)
- G9001 — Coordinated care fee, initial rate[Sibling]— CMS HCPCS Level II code set
- G9002 — Coordinated care fee, maintenance rate[Sibling]— CMS HCPCS Level II code set
- G9003 — Coordinated care fee, risk adjusted high, initial[Sibling]— CMS HCPCS Level II code set
- G9004 — Coordinated care fee, risk adjusted low, initial[Sibling]— CMS HCPCS Level II code set
- G9005 — Coordinated care fee, risk adjusted maintenance[Sibling]— CMS HCPCS Level II code set
- G9006 — Coordinated care fee, home monitoring[Sibling]— CMS HCPCS Level II code set
- G9007 — Coordinated care fee, scheduled team conference[Sibling]— CMS HCPCS Level II code set
- G9008 — Coordinated care fee, physician coordinated care oversight services[Sibling]— CMS HCPCS Level II code set
- and 32 more
Change history (2)
- January 1, 2020 — Removed from the code set [Change history]— CMS release files (code change ledger)
- and 1 more
Sources for this page
Codes, titles, notes, index terms and mappings on this page are transcribed from the datasets below. Relationships MedCoder computed and text MedCoder wrote are labelled where they appear.
- Code, descriptors, coverage and pricing attributes Official source data
- CMS HCPCS Alpha-Numeric (ANWEB) release — July 2026 quarterly update Release, file and checksum · Publisher’s page
- Change history and date-of-service validity Official source data
- CMS HCPCS quarterly update files, ingested into the change ledger Release, file and checksum · Publisher’s page
- Comparisons, relationships and the contextual map MedCoder structured relationship
- Computed by MedCoder from the tabular notes and tables above; every derived relationship is marked as derived where it appears
- Summary and FAQ answers MedCoder explanation
- Written by MedCoder to explain the sources above: drafted with AI assistance, checked by a person against the release files, and labelled as MedCoder text where it appears. Not official text.
Labels on this page: Official source data · MedCoder structured relationship · MedCoder explanation. How to read the labels · All data sources and release dates
Change history
- January 1, 2020Removed from the code setOseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)
- December 1, 2004Added to the code setOseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)
Nearest Codes in This Family
Official HCPCS Level II classifications closest to G9019 in its code family, with their registry titles.
- G9013 — Esrd demo basic bundle level i
- G9014 — Esrd demo expanded bundle including venous access and related services
- G9016 — Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
- G9017 — Amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- G9018 — Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
- G9020 — Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- G9033 — Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)
- G9034 — Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)
- G9035 — Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)
- G9036 — Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)